Cochrane · systematic review · CD008271
Botulinum toxin for shoulder pain
Singh, JA, Fitzgerald, PM · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
2
No studies
3
Included studies
NR
No studies 3 · 60%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 40%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with shoulder pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain (0‐10 cm visual analog scale)‐ Pain at 6‐12 weeks Visual Analog or Verbal Rating Scale. Scale from: 0 to 10. ( | no estimate extracted | 3 studies · 76 participants | Low Downgraded: risk of bias |
Number of Adverse Events (AEs) ( | RR 1.46 [0.64, 3.36] | 3 studies · 65 participants | Low Downgraded: risk of bias |
Disability/function ‐ not reported | no estimate extracted | NR | No studies |
WIthdrawals due to Adverse Events ‐ not reported | no estimate extracted | NR | No studies |
Serious Adverse Events ‐ not reported | no estimate extracted | NR | No studies |